Editorials

Adding Nails to the Coffin of Underpowered Trials
S.D. Halpern ................................................. 2065

Discovering That B Cells Are Important in Rheumatoid Arthritis
R.J. Looney ................................................. 2067

Can MRI of the Knee Predict Future Malalignment?
K.A. Syed, N.N. Mahomed ................................. 2070

Bones, Blood Vessels, and the Immune System: What’s the Link?
R.S.M. Yeung ............................................. 2072

Predictive Value of ANCA in Small-Vessel Vasculitis: Is the Glass Half Full or Half Empty?
C.A. Stegeman .............................................. 2075

Treatment of Hepatitis C Virus-Related Systemic Vasculitis
P. Cacoub, D. Saadoun, D. Sene, N. Limal, J-C. Piette ................................. 2078

Articles

The Prevalence of Underpowered Randomized Clinical Trials in Rheumatology
H.I. Keen, K. Pile, C.L. Hill ................................ 2083

The Predictive Value of RF Isotypes, Anti-CCP Antibodies, and ANCA for Mortality in Patients with RA
S. Sihvonen, M. Korpela, A. Mustila, J. Mustonen ................................ 2089

Effects of ACE Inhibition and Statin Treatment on Inflammatory Markers and Endothelial Functions in Patients with Longterm RA
C. Tikiz, O. Utuk, T. Pirildar, et al ................................ 2095

Modification of Pro- and Antiinflammatory Cytokines and Vascular-Related Molecules by TNF-α Blockade in Patients with RA
I. Macías, S. García-Pérez, M. Ruiz-Tudela, F. Medina, N. Chozas, J.A. Girón-González ........................................ 2102

Safety and Efficacy of Rituximab in Patients with RA Refractory to DMARD and Anti-TNF-α Treatment
J. Higashida, T. Wun, S. Schmidt, S.M. Naguwa, J.M. Tuscano ........................................ 2109

Anti-TNF-α Therapy Augments DPP IV Activity and Decreases Autoantibodies to GRP78/BIP and PGI in Patients with RA
J.C. Mavropoulos, M. Cuchacovich, C. Llanos, et al ........................................ 2116

Staphylococcus aureus in Patients with RA Under Conventional and Anti-TNF-α Treatment
S. Bassetti, S. Wasmer, P. Hasler, et al ........................................ 2125

Skin Cancer, RA, and TNF Inhibitors
E.F. Chakravarty, K. Michaud, F. Wolfe ........................................ 2130

Static Wrist Splint Use in the Performance of Daily Activities by Individuals with RA
A. Pagnotta, N. Korner-Bitensky, B. Mazer, M. Baron, S. Wood-Dauphinee ........................................ 2136

The Clinical Spectrum of ANA Associated with the Nuclear Dense Fine Speckled Immunofluorescence Pattern
A. Dellavance, V.S.T. Viana, E.P. Leon, E.S.D.O. Bonfa, L.E.C. Andrade, P.G. Leser ........................................ 2144

SLE in a Multiethnic Cohort (LUMINA): XXIX. Elevation of ESR Is Associated with Disease Activity and Damage Accrual
L.M. Vilá, G.S. Alarcón, G. McGwin Jr, H.M. Bastian, B.J. Fessler, J.D. Reveille, for the LUMINA Study Group ........................................ 2150

Enhanced Expression of Programmed Death-1 (PD-1) / PD-L1 in Salivary Glands of Patients with SS
M. Kobayashi, S. Kawano, S. Hatachi, et al ........................................ 2156

Serum Relaxin in SSc N. Giordano, P. Papakostas, B. Lucani, et al ........................................ 2164

Predictive Value of ANCA in Small-Vessel Vasculitis
F. Lurati-Ruiz, F. Spertini ........................................ 2167

IL-6 Promoter Polymorphism at Position –174 in GCA
C. Salvarani, B. Casali, E. Farnetti, et al ........................................ 2173

Association of a Functional INOS Promoter Variant with Susceptibility to Biopsy-Proven GCA
M.A. Gonzalez-Gay, J. Oliver, E. Sanchez, et al ........................................ 2178

Infliximab to Etanercept Switch in Patients with SpA and PsA: Preliminary Data
C. Delaunay, V. Farrenq, A. Marini-Portugal, J-D. Cohen, X. Chevalier, P. Claudepierre ........................................ 2183

Female Gout: Clinical and Laboratory Features
A.W.S. de Souza, V. Fernandes, A.J.L. Ferrari ........................................ 2186

Prevalence and Risk Factors for Urolithiasis in Primary Gout: Is a Reappraisal Needed?
J. Alvarez-Nemegyei, M. Medina-Escobedo, S. Villanueva-Jorge, J. Vazquez-Mellado ........................................ 2189

Contents continued on page iv

Relationship Between Bone Markers and Knee Cartilage Volume in Healthy Men  Y. Wang, P.R. Ebeling, F. Hanna, R. O’Sullivan, F.M. Cicuttini  2200

Increased MCP-1 in Knee Joints of Rats with AIA: In Vivo Microdialysis  S-H. Liu, C-S. Wong, D-M. Chang  2205

Risk of Hospitalization with Peptic Ulcer Disease or GI Hemorrhage Associated with Nabumetone, Arthrotec®, Diclofenac, and Naproxen in a Population Based Cohort Study  N.L. Ashworth, P.M. Peloso, N. Muhajarine, M. Stang  2212

Patterns of Use and Public Perception of OTC Pain Relievers: Focus on NSAID  C.M. Wilcox, B. Cryer, G. Triadafilopoulos  2218

Pediatric Rheumatology


OPG Serum Levels in Kawasaki Disease: An Additional Potential Marker in Predicting Children with Coronary Artery Involvement  G. Simonini, L. Masi, T. Giani, et al  2233

MRI in Pachydermodactyly  A. Anandacoomarasamy, H-S. Bak, A. Peduto, N. Manolios  2239

Case Report

Lymphomatoid Granulomatosis: A Rare Mimicker of Vasculitis  S.M. Wu, Y. Min, N. Ostrzega, P.J. Clements, A.L. Wong  2242

OMERACT 7

International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, Asilomar, California, USA, May 8-12, 2004  2246

Progress Since OMERACT 6 on Including Patient Perspective in RA Outcome Assessment  J.R. Kirwan, M. Ahlmen, M. de Wit, et al  2250

Incorporating the Patient Perspective into Outcome Assessment in RA — Progress at OMERACT 7  J.R. Kirwan, S.E. Hewlett, T. Heiberg, et al  2257

Attributes and Skills of an Effective Musculoskeletal Consumer  P.S. Tugwell, A.J. Wilson, P.M. Brooks, et al  2262

Outcome Measures in PsA  D.D. Gladman, P.J. Mease, G. Krueger, et al  2270

Fibromyalgia Syndrome  P.J. Mease, D.J. Clauw, L.M. Arnold, et al  2278

Correspondence

The Arthritis of Familial Mediterranean Fever  I. Uthman  2278

Reply  M. Lidar, A. Livneh  2278

Letter

Can Hand Assessments Designed for Persons with Scleroderma Be Valid for Persons with RA?  J.L. Poole, K.J. Cordova  2278

Corrections

J Rheumatol 2005; volume 32: number 8. Table of contents  2280

Ibuprofen May Abrogate the Benefits of Aspirin When Used for Secondary Prevention of Myocardial Infarction  M. Hudson, M. Baron, E. Rahme, L. Pilote  2280

Meetings in Rheumatology